Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is expanding into areas like cardiovascular diseases and increasing focus on treating conditions outside of its core diabetes and weight-loss market.
Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is expanding into areas like cardiovascular diseases and increasing focus on treating conditions outside of its core diabetes and weight-loss market.